Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Carbamylerythropoietin (CEPO) does not bind to the classical erythropoietin (EPO) receptor. Nevertheless, similarly to EPO, CEPO promotes neuroprotection on the histologic level in short-term stroke models. In the present study, we investigated whether CEPO and other nonerythropoietic EPO analogs could enhance functional recovery and promote long-term histologic protection after experimental focal cerebral ischemia. Rats were treated with the compounds after focal cerebral ischemia. Animals survived 1, 7, or 60 days and underwent behavioral testing (sensorimotor and foot-fault tests). Brain sections were stained and analyzed for Iba-1, myeloperoxidase, Tau-1, CD68 (ED1), glial fibrillary acidic protein (GFAP), Fluoro-Jade B staining, and overall infarct volumes. Treatment with CEPO reduced perifocal microglial activation ( P<0.05), polymorphomonuclear cell infiltration ( P<0.05), and white matter damage ( P<0.01) at 1 day after occlusion. Carbamylerythropoietin-treated rats showed better functional recovery relative to vehicle-treated animals as assessed 1, 7, 14, 28, and 50 days after stroke. Both GFAP and CD68 were decreased within the ipsilateral thalamus of CEPO-treated animals 60 days postoperatively ( P<0.01 and P<0.05, respectively). Furthermore, behavioral analysis showed efficacy of CEPO treatment even if administered 24 h after the stroke. Other nonerythropoietic derivatives such as carbamylated darbepoetin alfa and the mutant EPO-S100E were also found to protect against ischemic damage and to improve postischemic neurologic function. In conclusion, these results show that postischemic intravenous treatment with nonerythropoietic EPO derivatives leads to improved functional recovery, which may be linked to their long-term effects against neuroinflammation and secondary tissue damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943 · cited 2×
“Nevertheless, cortical infarct volume, as assessed by either direct (Figure 3C) or indirect (data not shown) calculation methods, was not significantly (P > 0.05) reduced in rats treated with CEPO administered 3 h or 3, 24, and 48 h after occlusion compared with the vehicle group (Figure 3C).”
BackgroundMethodInfluentialViability thresholds and the penumbra of focal ischemia
Hossmann, K. (1994) · Annals of Neurology · doi:10.1002/ana.410360404 · Cited by 1,370 · cited 2×
“In our stroke model, the temporary occlusion of the contralateral CCA produces a penumbra surrounding the fixed MCA lesion (Zimmerman et al, 1995) and a wide ischemic penumbra is a prerequisite for the occurrence of a delayed infarct expansion (Hossmann, 1994).”
BackgroundEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
Self-citation
Cited by
Angiogenesis after cerebral ischemia
Beck, H., & Plate, K. H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0483-6 · Cited by 383
Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy
Zhu, C., Kang, W., Xu, F., Cheng, X., Zhang, Z., Jia, L., Ji, L., Guo, X., Xiong, H., Simbruner, G., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-3553 · Cited by 354
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Brines, M., & Cerami, A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02024.x · Cited by 333
Self-citationNonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Brines, M., Patel, N. S. A., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Sepodes, B., Thiemermann, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805594105 · Cited by 319
Self-citationMolecular Mechanisms of Apoptosis in Cerebral Ischemia: Multiple Neuroprotective Opportunities
Nakka, V. P., Gusain, A., Mehta, S. L., & Raghubir, R. (2008) · Molecular Neurobiology · doi:10.1007/s12035-007-8013-9 · Cited by 261
Erythropoietin, erythropoiesis and beyond
Chateauvieux, S., Grigorakaki, C., Morceau, F., Dicato, M., & Diederich, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.045 · Cited by 180
From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease
Caprara, C., & Grimm, C. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.003 · Cited by 176
Neurorestorative treatment of stroke: Cell and pharmacological approaches
Chen, J., & Chopp, M. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.07.007 · Cited by 171
“and white matter damage, and significantly improves functional outcome after stroke.(73) Mechanisms of EPO-induced neurorestoration.”
BackgroundReitmeir, R., Kilic, E., Kilic, Ü., Bacigaluppi, M., ElAli, A., Salani, G., Pluchino, S., Gassmann, M., & Hermann, D. M. (2011) · Brain · doi:10.1093/brain/awq344 · Cited by 156
Chen, X.-R., Liao, S.-J., Ye, L.-X., Gong, Q., Ding, Q., Zeng, J.-S., & Yu, J. (2014) · Brain Research · doi:10.1016/j.brainres.2013.12.002 · Cited by 43
Metadata
- Authors
- Villa, P., van Beek, J., Larsen, A. K., Gerwien, J., Christensen, S., Cerami, A., Brines, M., Leist, M., Ghezzi, P., & Torup, L.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2007-03
- Volume
- 27
- Issue
- 3
- Pages
- 552-563
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2143708434
- Cited by
- 154
- References
- 3
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.